London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
discuss illegal or criminal activities.
post any confidential or price sensitive information or that is not public knowledge.
post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
post any personal details (e.g. email address or phone number).
post live price or level 2 updates.
publish content that is not your original work, or infringes the copyright or other rights of any third party.
post non-constructive, meaningless, one word (or short) non-sense posts.
post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
post any affiliate or referral links, or post anything asking for a referral.
post or otherwise publish any content unrelated to the board or the board's topic.
re-post premium share chat posts on regular share chat.
restrict or inhibit any other user from using the boards.
impersonate any person or entity, including any of our employees or representatives.
post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium and Verified Members
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
If you meant my post on the production of ifn vs antibodies I did actually make a mistake. One dose of ifn per sng trials is about 25 ug, 1000 times that is 25mg so actually it is more than 10000 times less protein weight than a dose of 300 mg of antibody. So I was off by an order of magnitude, it would actually be even cheaper to make 25 ug of ifn and 300mg of antibody than I suggested initially.
Doc, I am sorry but I missed the post about the email from the company confirming they had seen the initial results. Nevertheless I believe the protocol allows for a few people close to the trial within the company to see these early but still mainting the blinding as far as patients and doctors are concerned. Therefore it is quite possible that Ghia is correct and it is thought that an RNS release prior to the the last 90 day follow up could allow bias. Therefore it is still feasible that the early data may be released by RNS after that 90 day period has elapsed.
Meelie, I am sure you are correct that the BoD are not interested in the view of short term investors or traders and have consistently shown to date that they are only prepared to do things in a proper and considered manner with regard to the long term benefit of the company.
I also take on board the point that RNS's such as the one we are expecting are important and do take time to prepare. I recall there was a second RNS rushed out directly after the 20 July one for clarification. Therefore although it is possible that we will get 2 RNSs with the 60/90 day results separate and subsequent it is also possible that all will be rolled into one. In the latter case I think I am still sticking by my earlier view that we may not hear anything until 2 weeks either side of 24 May. I think I missed my chance this morning to top up in my new ISA but see my limit trade at 145p was actioned this morning and already in profit.
A nice little move up at the moment. Strong RSI. What's happened?
Correct Meelie, RNS can take weeks from point of writing to issuing officially - I think it was Jkman(?) that posted a very good CEO overviewof what goes into RNSs. It's not a quick email they bang up in the morning and issue the next day, or even the next week.
Spinnaker..... for the sake of the, relatively, short term investors it would've been great if he had released the HT in two parts. But I don't think his priority is to the short term investor. He has had very large investors with him since the beginning, who are happy waiting until the summer.... what's another few months, when they've been with him for 15 years of up and down.
I also remember listening to one interview when RM said that RNS's take a lot of time to put together... from reading the huge contents of past RNS's my feeling is that he will roll everything into the next RNS including the 90 day/long covid/Active 2 and anything else he can give news on. It would be nice if that was April, but am prepared for it to be May.
The science is good, the company is solid. I'm pretty relaxed about the short term SP..... but very excited about the next jump up!
Thanks to Tornadotony again.... your chart predictions are solid, and it's great having on this board. I have incidentally doubled my money on one of your share tips/timings in just a month.... so a big thank you for that!
Spin We heard from the company in an email reply to say that the management team have seen the data already. Not sure who wrote the letter or posted it. Couple of days ago. My concerns are the same - why wouldn't you get the 28 day results out as soon as they're analysed if they are strong or the 60 day ? And ;let 90 come along when it's ready. Ghia explained the bias issue though and I'm hoping that's what it's about
How long did that answer take to get? It must be at least 6 weeks. At least it was very positive and specific re SNG001. Possibly the first time I have seen anything official emanating from the government mentioning the company name. Are you able to post the link please.
However, in comparison to vaccines where orders were placed before authorisation and well before conclusion of trials, it is clear that there are no plans to contract orders before authorisation for use be that emergency use or not.
I am just considering whether to add to my holding at current SP but my confidence in AIM companies and government shenanigans has taken a knock since the unbelievable NCYT news.
I still am unsure why Synairgen appear not to be releasing the initial results for the home trial which they could have had by now. Is it the case that once the 90 day review had been incorporated into the trial they would not un-blind any of the results until all the information was collected due to possibility of bias? My slight concern is that they have already analysed the initial findings up to 28 or 30 days but have decided not to to release these if inconclusive or non-significant in the hope that the longer term analysis would strengthen the case. If the former scenario is correct and they have not yet un-blinded any results then I would feel a bit happier.
Overall I am still confident with the company and product but agree with most posters that the UK home trial results will probably not be sufficient in themselves to gain authorisation in the UK. I would love to be proved wrong.
Good find Mike - and potentially positive news for ramping up manufacturing.
We are definitely on the radar - it’s just a shame Matt Han****’s neighbour isn’t on the Board of Synairgen or we’d have EUA and orders already. A bit more patience required before the blockbuster RNS.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of placing advance orders for inhaled interferon beta, which is being trialled as a treatment for covid-19 in Newcastle’s Royal Victoria Infirmary and other hospitals.
12 April 2021 On 30 November, we announced a £20 million Medicines and Diagnostics Manufacturing Transformation Fund. This will offer capital grants to businesses, incentivising them to place internationally mobile high value manufacturing investment, such as the manufacturing interferon beta in the United Kingdom.
The Department has been working constructively with Synairgen to assist them in generating data in support of their inhaled interferon beta treatment, SNG001. We continue to monitor progress on SNG001 closely. However, purchasing of therapeutics will only be considered once there is sufficient evidence of safety and efficacy and the Medicines and Healthcare products Regulatory Agency has provided marketing authorisation.